Home › Research › Treatments
Galantamine plasma concentration and cognitive response in Alzheimer's disease
Yi-Ting Lin, Mei-Chuan Chou, Shyh-Jong Wu, Yuan-Han Yang. PeerJ, 2019-05-02
Topic: Drug trials: efficacy and safety
The total sample consisted of 33 clinically diagnosed AD patients taking galantamine 8 mg/d for 6 months. There was no linear correlation between galantamine concentration and cognitive response in patients. However, 22 patients were responsive to the treatment in the long-term memory domain. In CASI subset domain, concentration improved during the 6 months follow up. In the limited samples study, galantamine mostly benefitted the cognitive domain of long-term memory. The benefits were not related to the galantamine plasma concentration. Objective intra-individual evaluation of therapeutic response should be encouraged.
Key findings
- The total sample consisted of 33 clinically diagnosed AD patients taking galantamine 8 mg/d for 6 months.
- There was no linear correlation between galantamine concentration and cognitive response in patients.
- However, 22 patients were responsive to the treatment in the long-term memory domain.
- In CASI subset domain, concentration improved during the 6 months follow up.
- In the limited samples study, galantamine mostly benefitted the cognitive domain of long-term memory.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designcohort study
- Participants22
- Evidence strengthModerate
How this study scored 63/100
Published in a peer-reviewed journal, and it is a cohort study following people over time. Scored zero for effect reported and randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multi-centre collaboration and free to read, so those were left out: it earned 35 of the 56 points we could judge it on, which is 63 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (PeerJ) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2019 — within 10 year(s) of the newest study here |
| Sample size | 1 / 4 | 22 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 31106076) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 35 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 35 of the 56 points we could judge it on is 63 out of 100. |
| Total | 63 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
APA 7th
Lin, Y.-T., Chou, M.-C., Wu, S.-J., & Yang, Y.-H. (2019). Galantamine plasma concentration and cognitive response in Alzheimer's disease. PeerJ. https://doi.org/10.7717/peerj.6887
Vancouver
Lin Y.-T, Chou M.-C, Wu S.-J, Yang Y.-H. Galantamine plasma concentration and cognitive response in Alzheimer's disease. PeerJ. 2019. doi:10.7717/peerj.6887. PMID: 31106076.
BibTeX
@article{lin2019-31106076,
author = {Lin, Yi-Ting and Chou, Mei-Chuan and Wu, Shyh-Jong and Yang, Yuan-Han},
title = {{Galantamine plasma concentration and cognitive response in Alzheimer's disease}},
journal = {PeerJ},
year = {2019},
doi = {10.7717/peerj.6887},
pmid = {31106076},
url = {https://doi.org/10.7717/peerj.6887}
}
Related studies in Treatments
Also tagged “cholinesterase”
271 studies in the library carry the topic tag “cholinesterase”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 271 tagged studies.